<DOC>
	<DOCNO>NCT03065374</DOCNO>
	<brief_summary>This study evaluate safety tolerability IMM-529 together standard care ( SOC ) patient Clostridium-difficile Infection .</brief_summary>
	<brief_title>Treatment Clostridium-difficile Infection With IMM529</brief_title>
	<detailed_description>Subjects provide voluntary write informed consent screen eligibility . Subjects meet inclusion none exclusion criterion eligible participate . Eligible subject randomize 3 week post diagnosis Clostridium-difficile Infection give SOC initiate already . Each subject return study clinic assessment require study procedure Day 7 , Day 14 , Week 4 , Week 8 Week 12 post randomization . Treatment duration 28 day follow last 12 week post randomization .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<criteria>1 . Age â‰¥ 18 year 2 . Unformed stool positive stool test C. difficile PCR ( Polymerase chain reaction ) ELISA 3. 3 week diagnosis least 20 subject within 72 hour diagnosis 4 . Patient legal representative must read , understood , provide write informed consent nature study fully explain . 1 . History chronic diarrheal illness ulcerative colitis Crohn 's disease 2. etiology diarrhea 3 . Severe Complicated Disease 4 . Severe C. difficile colitis plan surgery le 24 hour . 5 . Immunocompromised subject due malignancy iatrogenic disease 6 . Positive pregnancy test within 24 hour study infusion unwillingness undergo pregnancy test female childbearing potential . Females capable childbearing must agree become pregnant time study enrollment least 28 day completion study treatment period . If woman sexually active history hysterectomy tubal ligation , must agree use 2 acceptable contraceptive ( see section 7.4.1 . ) participate study 28 day follow last dose study drug . 7 . Breastfeeding 8 . Receipt investigational study agent within previous 30 day . 9 . Cow milk allergy , lactose intolerance know suspected hypersensitivity study product 10 . Any condition opinion investigator would jeopardize safety right patient participate study make unlikely patient could complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>